Product Description
an enzyme replacement therapy using plant cell expression technology. aliglucerase alfa is a plant cell-expressed acid beta-glucosidase approved in the United States and other countries for ERT in adults with GD1. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/24630271/)
Mechanisms of Action: Glucocerebroside Hydrolyzer
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Brazil | Canada | Chile | Dominican Republic | European Medicines Agency | Israel | New Zealand | Peru | Russia | Serbia | South Africa | Taiwan | Turkey | Ukraine | United States | Uruguay
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/05/2026 |
News Article |
Protalix BioTherapeutics Letter to Stockholders |
|
12/17/2025 |
News Article |
Protalix Biotherapeutics and Secarna Pharmaceuticals Enter into Collaboration and Option Agreement |
|
11/06/2025 |
News Article |
Protalix BioTherapeutics to Announce Third Quarter 2025 Financial and Business Results on November 13, 2025 |
|
11/03/2025 |
News Article |
Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dosing Regimen of Every Four Weeks in the EU |